Hosted on MSN1mon
Valneva announces positive outcomes from chikungunya vaccine trialValneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback